172 related articles for article (PubMed ID: 35635757)
1. Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment.
Lazure P; Tomlinson JW; Kowdley KV; Magni P; Santos RD; Jacobs G; Murray S
Liver Int; 2022 Aug; 42(8):1772-1782. PubMed ID: 35635757
[TBL] [Abstract][Full Text] [Related]
2. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.
Anstee QM; Hallsworth K; Lynch N; Hauvespre A; Mansour E; Kozma S; Marino JP; Bottomley J; Piercy J; Higgins V
JHEP Rep; 2022 Jan; 4(1):100411. PubMed ID: 34977520
[TBL] [Abstract][Full Text] [Related]
3. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
Wessels DH; Rosenberg Z
World J Hepatol; 2021 Feb; 13(2):233-241. PubMed ID: 33708352
[TBL] [Abstract][Full Text] [Related]
4. A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.
Driessen S; de Jong VD; van Son KC; Klompenhouwer T; Colardelle Y; Alings M; Moreno C; Anker SD; Castro Cabezas M; Holleboom AG; Grobbee DE; Tushuizen ME
United European Gastroenterol J; 2023 Sep; 11(7):654-662. PubMed ID: 37563849
[TBL] [Abstract][Full Text] [Related]
5. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
6. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
7. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
8. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
9. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
10. Challenges in multiple sclerosis care: Results from an international mixed-methods study.
Péloquin S; Schmierer K; Leist TP; Oh J; Murray S; Lazure P
Mult Scler Relat Disord; 2021 May; 50():102854. PubMed ID: 33690086
[TBL] [Abstract][Full Text] [Related]
11. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
Lazure P; Sireci A; Subbiah V; Murray S; Grohé C; Sherman SI; Kelly E; Bubach P; Péloquin S
BMC Med Educ; 2023 Jun; 23(1):410. PubMed ID: 37277734
[TBL] [Abstract][Full Text] [Related]
12. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.
Zheng KI; Liu WY; Pan XY; Ma HL; Zhu PW; Wu XX; Targher G; Byrne C; Wang XD; Chen YP; Lu F; Zheng MH
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139603
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.
Rinella M; Cryer DR; Articolo A; Fisher T; Schneider J; Nadolsky K
BMC Gastroenterol; 2022 Jul; 22(1):335. PubMed ID: 35811319
[TBL] [Abstract][Full Text] [Related]
14. Preparing for the NASH Epidemic: A Call to Action.
Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
Gastroenterology; 2021 Sep; 161(3):1030-1042.e8. PubMed ID: 34416976
[TBL] [Abstract][Full Text] [Related]
15. Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm.
Lemmer P; Selbach N; Baars T; Porsch-Özcürümez M; Heider D; Canbay A; Sowa JP
Dig Dis; 2022; 40(5):644-653. PubMed ID: 34469884
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Tasneem AA; Luck NH; Majid Z
Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
[TBL] [Abstract][Full Text] [Related]
17. Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care.
Porayko MK; Articolo A; Cerenzia W; Coleman B; Patel D; Stacy S
J Multidiscip Healthc; 2022; 15():1533-1545. PubMed ID: 35898947
[TBL] [Abstract][Full Text] [Related]
18. Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis.
Cook N; Geier A; Schmid A; Hirschfield G; Kautz A; Schattenberg JM; Balp MM
JHEP Rep; 2020 Apr; 2(2):100081. PubMed ID: 32190823
[TBL] [Abstract][Full Text] [Related]
19. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
Ji HF; Sun Y; Shen L
Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
[TBL] [Abstract][Full Text] [Related]
20. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
